Published on 30/11/2025

CPV in Multi-Site Biosimilar Networks

Understanding CPP and CPV: Definitions and Importance

In the fast-evolving landscape of pharmaceutical manufacturing, especially in the realm of biosimilars, the concepts of Product Quality (PPQ) and Continued Process Verification (CPV) have become essential. The US FDA, EMA, and other regulatory bodies emphasize the importance of these frameworks in ensuring consistent quality across manufacturing sites and product batches.

PPQ refers to the successful demonstration of the pharmaceutical process’s robustness and reliability through validation activities, and it is typically articulated during the filing of a regulatory submission. On the other hand, CPV is a post-approval commitment that ensures processes remain in a state of control, leveraging regular monitoring and analysis of data to detect any deviations or changes in product quality.

For biosimilars, where a high level of similarity to the reference product must be established, a robust PPQ/CPV strategy is especially critical. Biosimilar analytical comparability, CQA mapping, fingerprint analytics, and process drift monitoring are key components that can support compliance with these frameworks.

Step 1: Establishing a Comprehensive PPQ Framework

The primary objective of establishing a comprehensive PPQ framework is to allow for sufficient evidence that a manufacturing process consistently delivers a product that meets its predetermined specifications. This includes both the setup of the framework and the accompanying methodologies, such as CQA mapping and Q5E comparability.

• Select and Document Critical Quality Attributes (CQAs): Define the CQAs based on the reference product to ensure parity, including physicochemical, biological, and functional attributes. Documentation must align with regulatory expectations, such as those stipulated by FDA and EMA.
• Process Characterization: Characterize the manufacturing process to identify potential variables that could impact CQAs. This typically involves evaluating historical data or conducting designed experiments.
• Risk Assessment: Utilize risk assessment methodologies, such as Failure Mode Effects Analysis (FMEA), to evaluate how variations in the process might affect CQAs, guiding the subsequent analytical comparability framework.

Step 2: CQA Mapping and Fingerprint Analytics

CQA mapping is a structured approach that aligns each critical quality attribute with specific process parameters. This method is pivotal as it helps identify where variations may occur during the changeovers or transfers between different sites within a multi-site biosimilar network.

Fingerprint analytics is an advanced technique that leverages sophisticated analytical technologies, such as high-resolution mass spectrometry and chromatographic methods for analyzing product attributes across different batches. By establishing a fingerprint or unique profile of the biosimilar product, companies can ascertain variations and similarities with the reference product.

In practice, this requires analytical method validation to ensure consistency and accuracy. Regulatory guidance, such as Q6B specifications, can provide invaluable insights into standard expectations for analytical comparability studies.

Step 3: Implementing Process Drift Monitoring

Process drift monitoring is an essential aspect of the CPV strategy for biosimilars, particularly in a multi-site network where variability can be introduced due to discrepancies in manufacturing techniques, equipment, or environmental controls.

Implementing an effective process drift monitoring system involves:

• Routine Data Collection: Consistently gather data from critical process parameters and CQAs throughout the production lifecycle.
• Statistical Trend Analysis: Apply statistical tools to analyze trends over time, assessing whether the production remains within established limits set forth during the PPQ phase.
• Descriptive Analytics and Reporting: Utilize findings to generate regular reports that highlight any deviations from the norm, supporting investigation into the underlying causes.

The importance of continuous data monitoring allows companies to address issues proactively, rather than reactively, thereby enhancing the overall product quality.

Step 4: Equivalence Testing and Bridging Justifications

Equivalence testing is foundational in demonstrating that a biosimilar is comparable to the reference product, focusing on the establishment of bridging justifications where differences may exist. This is paramount in ensuring compliance under guidelines outlined by the FDA and EMA regulatory requirements.

Employing equivalence testing involves:

• Defining the Equivalence Criteria: Establish predefined metrics for analytical comparisons focusing on the chosen CQAs, ensuring statistical significance as part of the regulatory submission.
• Conducting Statistical Analysis: Use rigorous statistical techniques to compare results from the biosimilar against the reference product, utilizing metrics such as confidence intervals and p-values to gauge equivalency.
• Documenting Bridging Justifications: Justify any deviations found during testing by documenting reasons and ensure adequate rationale is provided in regulatory submissions to manage expectations for product quality.

Step 5: Developing a Dossier-Ready Summary

Creating a dossier-ready summary is the final pivotal step in illustrating the groundwork laid through the PPQ/CPV strategy, encompassing the data gathered from CQA mapping, fingerprint analytics, process drift monitoring, and equivalence testing.

This summary serves crucial regulatory submission purposes, thus it must include:

• Executive Summary: A concise overview encapsulating the objectives, methodologies, and findings of the PPQ and CPV strategies employed.
• Detailed Data Presentation: Include comprehensive analytical data and supportive evidence that demonstrates equivalency, processes, and any corrective actions taken based on drift monitoring findings.
• Compliance Statements: Clearly articulate the compliance with the latest regulatory guidance provided by the relevant health authorities, ensuring that the frameworks discussed have been thoroughly vetted against criteria from bodies like PIC/S.

Incorporating a dossier-ready summary not only aids regulatory reviews but enhances stakeholder confidence, highlighting due diligence in quality assurance.

Conclusion: Continuous Improvement and Regulatory Alignment

The pharmaceutical landscape requires stringent adherence to quality practices, especially in multi-site biosimilar networks. Implementing a robust PPQ/CPV strategy is not a finite task but a continuous commitment to process improvements and compliance with regulatory mandates.

Professionals in pharmaceutical operations, regulatory affairs, and quality control must ensure that principles surrounding biosimilar analytical comparability, CQA mapping, fingerprint analytics, and ongoing process monitoring remain at the forefront. With concentrated efforts geared towards maintaining quality integrity, organizations will not only achieve compliance but also foster trust in their biosimilar offerings.

By following these comprehensive steps, organizations can develop a clear roadmap towards successful biosimilar product development and regulatory submissions, underlining the importance of adhering to established quality standards as outlined by the WHO.